Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

2700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-12

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational, retrospective, cohort, safety study in pregnant women (vaccinated with Pertagen®) and have given birth in Thailand from January 2021 to April 2024 and infants born to pregnant women who received Pertagen®.

Following approval of the final protocol from the Institutional Review Board (IRB) and/or Ethics Committee (EC) and written approval from hospital directors/medical doctors as per requirements of each institutions. The assigned Ob-gyn specialist/physician at each study site will review the medical record of pregnant women (January 2020 to April 2024) based on study selection criteria. Safety information of pregnant women who received Pertagen® and have given birth from January 2021 to April 2024 and infants born to pregnant women who received Pertagen® will be obtained from medical records in hospitals/clinics and will be reported in case report form (CRF) by assigned Ob-gyn specialist/physician at each study site. The assigned Ob-gyn specialist/physician at each study site who will review the medical records and report the data in case report form (CRF) is not part of the research team.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

NCT02408926

Pertussis

COMPLETED PHASE4

Pertussis (Tdap) Vaccination in Pregnancy

NCT01698346

Pertussis Pregnancy

COMPLETED PHASE4

Vaccination In Pregnancy Gene Signature: VIP Signature Study

NCT03284515

Pregnancy Related Vaccination

COMPLETED

Optimising the Timing of Whooping Cough Immunisation in MUMs

NCT03908164

UNKNOWN PHASE4

Pertussis Vaccination in Pregnant Women

NCT03909126

Pertussis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A CRF has been developed and will be used to collect safety information on pregnancy outcomes including the health status of infants at birth. The following definitions will be used for data collection

* The 2nd trimester of pregnancy is defined as gestational period between 13-26 weeks
* The 3rd trimester of pregnancy is defined as gestational period from 27 weeks to delivery.
* Full term birth is defined as delivery of a baby at gestational age (GA) ≥37 weeks.
* Preterm birth is defined as delivery of a baby at GA\<37 weeks.
* Complications during delivery may include postpartum hemorrhage, maternal fever or infection, or any maternal and fetal indications that may require emergency caesarean section.
* Safety information of pregnancy and delivery outcome refers to health of women during pregnancy and childbirth (WHO 2024). The most common direct causes of maternal injury and death are excessive blood loss, infection, high blood pressure, unsafe abortion, and obstructed labor, as well as indirect causes such as anemia and heart disease (WHO 2024).
* A newborn is defined as healthy at birth if discharged from the hospital in the first few days of life.
* A newborn is defined as not healthy if with difficulty of breathing, congenital abnormality or other conditions that would require prolonged stay at the hospital.

To ensure the privacy and confidentiality of the collected data, strict adherence to all relevant data protection regulations will be followed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pertussis Vaccines Pertussis (Whooping Cough)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women received Pertagen® and have given birth in Jan 2021-Apr 2024 and their infants

The pregnant women (previously vaccinated with Pertagen®) and have given birth in Thailand from Jan 2021 - Apr 2024 and infants born to pregnant women who received Pertagen®.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Data of pregnant women previously vaccinated with Pertagen® during second or third trimester of pregnancy and have given birth in Thailand from January 2021 to April 2024 and infants born to pregnant women who received Pertagen® during pregnancy.
2. Infant of pregnant women who received Pertagen® during second or third trimester of pregnancy